Apr 16 |
Institutional investors may adopt severe steps after Erasca, Inc.'s (NASDAQ:ERAS) latest 11% drop adds to a year losses
|
Apr 1 |
Erasca, Inc. (NASDAQ:ERAS) Q4 2023 Earnings Call Transcript
|
Mar 29 |
Erasca, Inc. (ERAS) R&D Update Call and Q4 2023 Earnings Call Transcript
|
Mar 29 |
Erasca Inc (ERAS) Aligns with EPS Projections, Reveals Robust Balance Sheet and Key Clinical ...
|
Mar 28 |
Erasca to get $45M funding via private placement
|
Mar 28 |
Erasca Announces $45 Million Oversubscribed Private Placement Financing
|
Mar 27 |
Erasca GAAP EPS of -$0.20
|
Mar 27 |
Erasca Reports Fourth Quarter 2023 and Full Year 2023 Business Updates and Financial Results
|
Feb 14 |
Erasca Announces Two Clinical Trial Collaboration and Supply Agreements for Trametinib to Evaluate Naporafenib Combination in SEACRAFT-1 and SEACRAFT-2 Trials
|
Feb 1 |
Erasca to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
|